GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Emyria Ltd (ASX:EMD) » Definitions » Asset Impairment Charge

Emyria (ASX:EMD) Asset Impairment Charge : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Emyria Asset Impairment Charge?

Emyria's Asset Impairment Charge for the six months ended in Dec. 2023 was A$0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.


Emyria Asset Impairment Charge Historical Data

The historical data trend for Emyria's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emyria Asset Impairment Charge Chart

Emyria Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Asset Impairment Charge
- - - - -

Emyria Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Impairment Charge Get a 7-Day Free Trial - - - - -

Emyria Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.


Emyria Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Emyria's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


Emyria (ASX:EMD) Business Description

Traded in Other Exchanges
N/A
Address
D2 661 Newcastle Street, PO Box 1442, Leederville, WA, AUS, 6007
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.

Emyria (ASX:EMD) Headlines

From GuruFocus